The effect of imatinib and nilotinib on blood calcium and blood potassium levels in chronic myeloid leukemia patient: a literature review

Imatinib and nilotinib are first-line treatments for chronic myeloid leukemia (CML) patients, which act specifically against target cells. However, these drugs may cause side effects, such as electrolyte disturbances. This literature review aimed to provide a comparison of the effects of imatinib a...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Muhammad Darwin Prenggono, Alfi Yasmina, Misna Ariyah, Tenri Ashari Wanahari, Nuvita Hasrianti
Formato:	article
Lenguaje:	EN
Publicado:	PAGEPress Publications 2021
Materias:	tyrosine kinase inhibitors chronic myeloid leukemia electrolytes imatinib nilotinib potassium Other systems of medicine RZ201-999 Internal medicine RC31-1245
Acceso en línea:	https://doaj.org/article/4a95a91f1fce4f65843fdb59d347e853
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:4a95a91f1fce4f65843fdb59d347e853
record_format	dspace
spelling	oai:doaj.org-article:4a95a91f1fce4f65843fdb59d347e8532021-11-27T12:42:50ZThe effect of imatinib and nilotinib on blood calcium and blood potassium levels in chronic myeloid leukemia patient: a literature review10.4081/oncol.2021.5471970-55571970-5565https://doaj.org/article/4a95a91f1fce4f65843fdb59d347e8532021-11-01T00:00:00Zhttps://www.oncologyreviews.org/site/article/view/547https://doaj.org/toc/1970-5557https://doaj.org/toc/1970-5565 Imatinib and nilotinib are first-line treatments for chronic myeloid leukemia (CML) patients, which act specifically against target cells. However, these drugs may cause side effects, such as electrolyte disturbances. This literature review aimed to provide a comparison of the effects of imatinib and nilotinib on blood potassium and calcium levels. It also summarized their hypothetical mechanism. A comprehensive electronic search of the different databases was conducted using "chronic myeloid leukemia”, “tyrosine kinase inhibitors”, “imatinib”, “nilotinib”, “potassium”, “calcium”, “electrolytes” as keywords. This review used Pubmed-MEDLINE, Cochrane Library, and Google Scholar as electronic databases. Related 16 articles published from 2006 to 2020 were reviewed. Changes in blood potassium levels range from increased to decreased levels, while changes in blood calcium levels tend to below the normal value. Tyrosine Kinase Inhibitors (TKIs), including imatinib and nilotinib, have a non-specific target, namely platelet-derived growth factor receptor (PDGFR), which indirectly affects blood potassium and calcium levels in CML patients. The clinical manifestations of these changes vary from being visible only in laboratory tests to displaying a variety of signs and symptoms. Muhammad Darwin PrenggonoAlfi YasminaMisna AriyahTenri Ashari WanahariNuvita HasriantiPAGEPress Publicationsarticletyrosine kinase inhibitorschronic myeloid leukemiaelectrolytesimatinibnilotinibpotassiumOther systems of medicineRZ201-999Internal medicineRC31-1245ENOncology Reviews, Vol 15, Iss 2 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	tyrosine kinase inhibitors chronic myeloid leukemia electrolytes imatinib nilotinib potassium Other systems of medicine RZ201-999 Internal medicine RC31-1245
spellingShingle	tyrosine kinase inhibitors chronic myeloid leukemia electrolytes imatinib nilotinib potassium Other systems of medicine RZ201-999 Internal medicine RC31-1245 Muhammad Darwin Prenggono Alfi Yasmina Misna Ariyah Tenri Ashari Wanahari Nuvita Hasrianti The effect of imatinib and nilotinib on blood calcium and blood potassium levels in chronic myeloid leukemia patient: a literature review
description	Imatinib and nilotinib are first-line treatments for chronic myeloid leukemia (CML) patients, which act specifically against target cells. However, these drugs may cause side effects, such as electrolyte disturbances. This literature review aimed to provide a comparison of the effects of imatinib and nilotinib on blood potassium and calcium levels. It also summarized their hypothetical mechanism. A comprehensive electronic search of the different databases was conducted using "chronic myeloid leukemia”, “tyrosine kinase inhibitors”, “imatinib”, “nilotinib”, “potassium”, “calcium”, “electrolytes” as keywords. This review used Pubmed-MEDLINE, Cochrane Library, and Google Scholar as electronic databases. Related 16 articles published from 2006 to 2020 were reviewed. Changes in blood potassium levels range from increased to decreased levels, while changes in blood calcium levels tend to below the normal value. Tyrosine Kinase Inhibitors (TKIs), including imatinib and nilotinib, have a non-specific target, namely platelet-derived growth factor receptor (PDGFR), which indirectly affects blood potassium and calcium levels in CML patients. The clinical manifestations of these changes vary from being visible only in laboratory tests to displaying a variety of signs and symptoms.
format	article
author	Muhammad Darwin Prenggono Alfi Yasmina Misna Ariyah Tenri Ashari Wanahari Nuvita Hasrianti
author_facet	Muhammad Darwin Prenggono Alfi Yasmina Misna Ariyah Tenri Ashari Wanahari Nuvita Hasrianti
author_sort	Muhammad Darwin Prenggono
title	The effect of imatinib and nilotinib on blood calcium and blood potassium levels in chronic myeloid leukemia patient: a literature review
title_short	The effect of imatinib and nilotinib on blood calcium and blood potassium levels in chronic myeloid leukemia patient: a literature review
title_full	The effect of imatinib and nilotinib on blood calcium and blood potassium levels in chronic myeloid leukemia patient: a literature review
title_fullStr	The effect of imatinib and nilotinib on blood calcium and blood potassium levels in chronic myeloid leukemia patient: a literature review
title_full_unstemmed	The effect of imatinib and nilotinib on blood calcium and blood potassium levels in chronic myeloid leukemia patient: a literature review
title_sort	effect of imatinib and nilotinib on blood calcium and blood potassium levels in chronic myeloid leukemia patient: a literature review
publisher	PAGEPress Publications
publishDate	2021
url	https://doaj.org/article/4a95a91f1fce4f65843fdb59d347e853
work_keys_str_mv	AT muhammaddarwinprenggono theeffectofimatinibandnilotinibonbloodcalciumandbloodpotassiumlevelsinchronicmyeloidleukemiapatientaliteraturereview AT alfiyasmina theeffectofimatinibandnilotinibonbloodcalciumandbloodpotassiumlevelsinchronicmyeloidleukemiapatientaliteraturereview AT misnaariyah theeffectofimatinibandnilotinibonbloodcalciumandbloodpotassiumlevelsinchronicmyeloidleukemiapatientaliteraturereview AT tenriashariwanahari theeffectofimatinibandnilotinibonbloodcalciumandbloodpotassiumlevelsinchronicmyeloidleukemiapatientaliteraturereview AT nuvitahasrianti theeffectofimatinibandnilotinibonbloodcalciumandbloodpotassiumlevelsinchronicmyeloidleukemiapatientaliteraturereview AT muhammaddarwinprenggono effectofimatinibandnilotinibonbloodcalciumandbloodpotassiumlevelsinchronicmyeloidleukemiapatientaliteraturereview AT alfiyasmina effectofimatinibandnilotinibonbloodcalciumandbloodpotassiumlevelsinchronicmyeloidleukemiapatientaliteraturereview AT misnaariyah effectofimatinibandnilotinibonbloodcalciumandbloodpotassiumlevelsinchronicmyeloidleukemiapatientaliteraturereview AT tenriashariwanahari effectofimatinibandnilotinibonbloodcalciumandbloodpotassiumlevelsinchronicmyeloidleukemiapatientaliteraturereview AT nuvitahasrianti effectofimatinibandnilotinibonbloodcalciumandbloodpotassiumlevelsinchronicmyeloidleukemiapatientaliteraturereview
_version_	1718408984073863168

The effect of imatinib and nilotinib on blood calcium and blood potassium levels in chronic myeloid leukemia patient: a literature review

Ejemplares similares